Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
38.26
+1.25 (+3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
7 Cheap Biotech Stocks With Major Upside Potential
↗
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
↗
July 01, 2024
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
↗
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
↗
June 21, 2024
Via
Benzinga
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
↗
May 14, 2024
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Via
Benzinga
Topics
Cannabis
Key Takeaways From Harmony Biosciences Analyst Ratings
↗
April 30, 2024
Via
Benzinga
Evaluating Harmony Biosciences: Insights From 8 Financial Analysts
↗
March 28, 2024
Via
Benzinga
Analyst Ratings For Harmony Biosciences
↗
February 22, 2024
Via
Benzinga
Harmony Biosciences (HRMY) Q1 2024 Earnings Call Transcript
↗
April 30, 2024
HRMY earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024
↗
April 30, 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
↗
April 30, 2024
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with...
Via
Benzinga
Topics
Earnings
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy
April 30, 2024
From
Harmony Biosciences
Via
GlobeNewswire
Updates: HRMY, MELI, SWAV
↗
February 28, 2024
Another day, another slew of quarterly update reports for our followed stocks.
Via
Talk Markets
NASDAQ:HRMY stands out as a growth opportunity that won't break the bank.
↗
January 10, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
Via
Chartmill
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 6 Analysts
↗
January 02, 2024
Via
Benzinga
Harmony Biosciences (HRMY) Q4 2023 Earnings Call Transcript
↗
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 22, 2024
From
Harmony Biosciences
Via
GlobeNewswire
The 3 Most Undervalued Small-Cap Stocks to Buy in February 2024
↗
February 12, 2024
Small-cap stocks are the first ones to rally on a new business cycle, such as the business cycle starting recently.
Via
InvestorPlace
The 3 Most Undervalued Russell 2000 Stocks to Buy in February 2024
↗
February 07, 2024
Although the high-flying entities still capture Wall Street’s attention, astute investors should look to undervalued Russell 2000 stocks.
Via
InvestorPlace
NASDAQ:HRMY: good value for what you're paying.
↗
January 25, 2024
In a market where value is scarce, HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
Investors should take notice of NASDAQ:HRMY—it offers a great deal for the fundamentals it presents.
↗
January 03, 2024
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Why Harmony Biosciences Stock Got Slammed Today
↗
January 02, 2024
The commercial-stage company was dinged by a bearish new take from a researcher.
Via
The Motley Fool
2023 Year In Review
↗
January 02, 2024
The S&P 500 had a strong year in 2023, returning about 24% to investors from the beginning of the year to the end. Some of that was a bounce back from a poor 2022 when it was down over 11%.
Via
Talk Markets
Topics
Stocks
NASDAQ:HRMY is showing good growth, while it is not too expensive.
↗
December 18, 2023
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) stands out as a growth opportunity that won't break the bank.
Via
Chartmill
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
↗
December 17, 2023
While the broader healthcare sector offers myriad opportunities, these undervalued biotech picks could offer robust upside.
Via
InvestorPlace
NASDAQ:HRMY, an undervalued stock with good fundamentals.
↗
December 13, 2023
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye On
↗
December 07, 2023
Although Russell 2000 stocks may operate in the lightweight category, these entities could potentially provide a knockout punch.
Via
InvestorPlace
Looking for growth without the hefty price tag? Consider NASDAQ:HRMY.
↗
November 27, 2023
Investors seeking growth at a reasonable cost should explore HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY).
Via
Chartmill
NASDAQ:HRMY is probably undervalued for the fundamentals it is displaying.
↗
November 22, 2023
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
↗
November 03, 2023
Investors should take note ofHARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock that remains attractively priced.
Via
Chartmill
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
